North America ECG Devices Market Size, Share, and Growth Forecast 2026 - 2033

The North America ECG devices market size is expected to be valued at US$ 2.4 billion in 2026 and projected to reach US$ 3.9 billion by 2033, growing at a CAGR of 7.0% between 2026 and 2033.

Rising prevalence of cardiovascular disease alongside the expansion of outpatient cardiac diagnostic capacity is the primary force propelling this growth trajectory. The American Heart Association reports that nearly 128 million adults in the U.S. live with some form of cardiovascular disease, sustaining high volumes of routine ECG screening across care settings. Favorable Centers for Medicare & Medicaid Services (CMS) reimbursement policies for ambulatory cardiac monitoring are accelerating the adoption of Holter and stress testing systems in outpatient and clinic environments.

Drivers - Rising Burden of Cardiovascular Disease Across the Region

Cardiovascular disease remains the leading cause of death in North America, creating consistent demand for diagnostic electrocardiography equipment. According to the Centers for Disease Control and Prevention (CDC), heart disease accounts for nearly 1 in 5 deaths in the U.S., claiming more than 702,000 lives annually. The Heart and Stroke Foundation of Canada similarly reports that heart disease and stroke together are responsible for roughly 1 in 5 deaths among Canadians.

This persistent disease burden compels hospitals, diagnostic centers, and clinics to expand their cardiac screening capacity, directly increasing procurement of ECG Resting Systems and Holter Monitoring Systems. As preventive cardiology gains institutional priority, healthcare providers are investing in higher-throughput ECG platforms, reinforcing steady equipment replacement cycles and supporting long-term market expansion across the region.

Expansion of Ambulatory and Outpatient Cardiac Diagnostic Infrastructure

The steady shift of cardiac diagnostics from inpatient hospital settings toward ambulatory surgical centers and standalone diagnostic clinics is a major growth driver. CMS data indicates there are more than 5,900 Medicare-certified ambulatory surgical centers operating in the U.S., many of which now offer outpatient stress testing and Holter monitoring services. This decentralization lowers per-procedure costs and improves patient access to routine cardiac screening, encouraging higher device turnover among outpatient providers.

Complementing this, insurers including CMS and private payers have broadened reimbursement coverage for ambulatory ECG procedures, making outpatient cardiac diagnostics more financially viable for smaller clinics. As a result, equipment manufacturers such as Nihon Kohden Corporation and Spacelabs Healthcare, Inc. are prioritizing compact, cost-efficient ECG systems tailored to this expanding outpatient care segment.

Restraints - High Cost of Advanced ECG Systems and Reimbursement Constraints

Advanced ECG platforms integrating AI-based interpretation and wireless connectivity carry substantially higher upfront costs than conventional resting ECG units, restricting adoption among smaller clinics and rural providers. Reimbursement rates set by CMS for certain cardiac monitoring codes have not kept pace with device acquisition and maintenance costs, discouraging capital investment among independent diagnostic centers. Smaller ambulatory surgical centers, in particular, often defer upgrading legacy systems due to budget constraints, extending equipment replacement cycles. This cost sensitivity is particularly pronounced outside major metropolitan hospital networks, where capital budgets are tighter, thereby moderating the overall pace of technology upgrades across the North America ECG devices market.

Opportunities - Rising Adoption of Wireless and AI-Enabled ECG Monitoring Technologies

The integration of artificial intelligence and wireless connectivity into ECG devices is unlocking substantial growth potential for the North America ECG devices market. Products such as iRhythm Technologies, Inc.'s Zio long-term continuous monitoring patch have demonstrated how single-use, wearable ECG sensors can extend diagnostic monitoring beyond hospital walls while improving arrhythmia detection rates.

The U.S. Food and Drug Administration (FDA) has cleared multiple AI-based ECG interpretation algorithms in recent years, reflecting regulatory support for automated diagnostics that reduce technician workload. As hospitals and diagnostic centers seek to manage rising patient volumes with limited specialist availability, AI-enabled ECG Resting Systems and Holter Monitoring Systems that flag abnormalities automatically are becoming a priority procurement category. This convergence of software intelligence and wearable hardware presents manufacturers a significant avenue to differentiate their portfolios and capture premium pricing.

Product Analysis

The ECG Resting System segment led the North America ECG devices market, commanding approximately 54% share of category revenue in 2026. This dominance stems from the segment's role as the standard first-line diagnostic tool used across virtually every hospital emergency department, primary care clinic, and diagnostic center for routine cardiac assessment.

Resting ECG systems are comparatively affordable, require minimal specialized training, and benefit from broad FDA 510(k) clearance pathways that have enabled rapid product refreshes from manufacturers such as GE HealthCare and Koninklijke Philips N.V. Widespread integration of resting ECG units into routine annual physical examinations and pre-operative cardiac screening protocols further cements their leading position. Meanwhile, the ECG Stress Testing System segment is projected to expand fastest through 2033, driven by rising demand for exercise-based cardiac risk stratification among aging populations.

End-user Analysis

Hospitals represented the leading end-user segment in the North America ECG devices market, accounting for an estimated 45% share of end-user revenue in 2026. Hospitals maintain comprehensive cardiac care infrastructure, including emergency departments, intensive care units, and cardiology wards, that require continuous access to resting, Holter, and stress testing ECG systems for both acute and elective patient care.

High patient throughput and the need for immediate diagnostic turnaround make hospitals the largest procurers of multi-parameter ECG platforms, often sourced from established suppliers like Nihon Kohden Corporation and Fukuda Denshi Co., Ltd. Ambulatory Surgical Centers, in contrast, represent the fastest-growing end-user segment, benefiting from the broader shift toward outpatient procedures and supportive CMS reimbursement expansion for same-day cardiac diagnostic services across the region.

North America ECG Devices Market Trends and Insights

North America remains anchored by a mature, technology-forward healthcare system, with cardiac diagnostics increasingly shifting toward outpatient and remote monitoring settings. Growing preventive screening initiatives, expanding telehealth reimbursement, and steady replacement of legacy hospital ECG equipment are shaping regional demand. Strong regulatory support from the FDA and Health Canada continues to encourage adoption of connected, software-enabled ECG platforms across both countries.

U.S. ECG Devices Market Size

The U.S. dominated the North America ECG devices market, holding approximately 88% regional share in 2025, supported by an estimated market value exceeding US$ 2 billion in 2026. Extensive hospital networks, high cardiovascular disease prevalence reported by the CDC, and favorable CMS reimbursement for ambulatory cardiac monitoring continue to justify the country's outsized contribution to regional revenue.

Canada ECG Devices Market Size

Canada is projected to be the fastest-growing market within North America through 2033, aided by provincial investments in virtual cardiac care and expanding diagnostic imaging capacity. The Heart and Stroke Foundation of Canada highlights rising cardiovascular risk among an aging population, prompting Health Canada-supported procurement of Holter and stress testing systems across public hospital networks and community clinics.

The North America ECG devices market is moderately consolidated, with established medical technology companies such as GE HealthCare and Koninklijke Philips N.V. commanding significant share alongside specialized cardiac diagnostics providers.

Competitive strategy centers on continuous research and development investment in AI-enabled interpretation software, wireless connectivity, and miniaturized wearable form factors. Key differentiators among leaders include proprietary arrhythmia-detection algorithms, integration with hospital electronic health record systems, and expanding service-based monitoring subscriptions. Strategic partnerships, product line extensions through acquisitions such as Baxter International's cardiac monitoring portfolio, and geographic expansion into ambulatory care networks characterize recent competitive activity.

Emerging players are increasingly adopting subscription-based, remote patient monitoring business models to diversify revenue beyond one-time hardware sales.

Key Developments:

• In January 2026, AliveCor received U.S. Food and Drug Administration (FDA) clearance for the next generation of KAI 12L, the AI engine powering the Kardia 12L ECG System, enabling detection of five additional cardiac determinations and increasing the total number of cleared determinations to 39.
• In September 2025, AliveCor announced the launch of its Kardia 12L electrocardiogram (ECG) system in India, introducing the world’s first AI-powered handheld 12-lead ECG system featuring a single-cable design.
• In December 2024, DocGo Inc. broadened its partnership with SHL Telemedicine to integrate the SmartHeart® portable 12-lead ECG device across DocGo mobile health care units. Initially launched in New York, this extended partnership will now provide cutting-edge cardiovascular diagnostics to patients' homes and underserved areas in other markets.